MedTrace Logo

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

NCT05898399 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 181

Last updated 2026-05-01

No results posted yet for this study

Summary

This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.

Conditions

  • Advanced Solid Tumor
  • Metastatic Solid Tumor

Interventions

DRUG

ART6043

ART6043 will be given orally.

DRUG

Olaparib

Olaparib will be given orally.

Sponsors & Collaborators

  • Artios Pharma Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2028-06-30
Completion
2028-09-30
FDA Drug
Yes

Countries

  • United States
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05898399 on ClinicalTrials.gov